Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
MicroRNAs and triple negative breast cancer.

International journal of molecular sciences

D'Ippolito E, Iorio MV.
PMID: 24284394
Int J Mol Sci. 2013 Nov 11;14(11):22202-20. doi: 10.3390/ijms141122202.

Triple Negative Breast Cancer (TNBC) is a very aggressive tumor subtype, which still lacks specific markers for an effective targeted therapy. Despite the common feature of negativity for the three most relevant receptors (ER, PgR and HER2), TNBC is...

Cite
D'Ippolito E, Iorio MV. MicroRNAs and triple negative breast cancer. Int J Mol Sci. 2013;14(11):22202-20doi: 10.3390/ijms141122202.
D'Ippolito, E., & Iorio, M. V. (2013). MicroRNAs and triple negative breast cancer. International journal of molecular sciences, 14(11), 22202-20. https://doi.org/10.3390/ijms141122202
D'Ippolito, Elvira, and Iorio, Marilena V. "MicroRNAs and triple negative breast cancer." International journal of molecular sciences vol. 14,11 (2013): 22202-20. doi: https://doi.org/10.3390/ijms141122202
D'Ippolito E, Iorio MV. MicroRNAs and triple negative breast cancer. Int J Mol Sci. 2013 Nov 11;14(11):22202-20. doi: 10.3390/ijms141122202. PMID: 24284394; PMCID: PMC3856060.
Copy Download .nbib Format: NLM
Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer.

Cancer cell

Koh SB, Ellisen LW.
PMID: 34767761
Cancer Cell. 2021 Dec 13;39(12):1562-1564. doi: 10.1016/j.ccell.2021.11.001. Epub 2021 Nov 11.

Immune checkpoint blockade plus chemotherapy is emerging as a standard treatment for some patients with triple-negative breast cancer (TNBC). In this issue of Cancer Cell, Zhang et al. employ extensive single-cell immune compartment analyses of pre- and post-therapy TNBC,...

Cite
Koh SB, Ellisen LW. Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer. Cancer Cell. 2021;39(12):1562-1564doi: 10.1016/j.ccell.2021.11.001.
Koh, S. B., & Ellisen, L. W. (2021). Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer. Cancer cell, 39(12), 1562-1564. https://doi.org/10.1016/j.ccell.2021.11.001
Koh, Siang-Boon, and Ellisen, Leif W. "Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer." Cancer cell vol. 39,12 (2021): 1562-1564. doi: https://doi.org/10.1016/j.ccell.2021.11.001
Koh SB, Ellisen LW. Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer. Cancer Cell. 2021 Dec 13;39(12):1562-1564. doi: 10.1016/j.ccell.2021.11.001. Epub 2021 Nov 11. PMID: 34767761.
Copy Download .nbib Format: NLM
Basal-like and triple-negative breast cancers: searching for positives among many negatives.

Surgical oncology clinics of North America

Alluri P, Newman LA.
PMID: 24882351
Surg Oncol Clin N Am. 2014 Jul;23(3):567-77. doi: 10.1016/j.soc.2014.03.003.

Triple-negative breast cancers (TNBC) are defined by their failure to express the estrogen receptor, progesterone receptor, and HER2/neu protein markers. This basic feature is clinically relevant because it indicates that these cancers cannot be managed with endocrine or anti-HER2...

Cite
Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am. 2014;23(3):567-77doi: 10.1016/j.soc.2014.03.003.
Alluri, P., & Newman, L. A. (2014). Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surgical oncology clinics of North America, 23(3), 567-77. https://doi.org/10.1016/j.soc.2014.03.003
Alluri, Prasanna, and Newman, Lisa A. "Basal-like and triple-negative breast cancers: searching for positives among many negatives." Surgical oncology clinics of North America vol. 23,3 (2014): 567-77. doi: https://doi.org/10.1016/j.soc.2014.03.003
Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am. 2014 Jul;23(3):567-77. doi: 10.1016/j.soc.2014.03.003. PMID: 24882351; PMCID: PMC4304394.
Copy Download .nbib Format: NLM
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?.

Oncotarget

Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT.
PMID: 25973541
Oncotarget. 2015 May 30;6(15):12890-908. doi: 10.18632/oncotarget.3849.

Significant research has been conducted to better understand the extensive, heterogeneous molecular features of triple-negative breast cancer (TNBC). We reviewed published TNBC molecular classifications to identify major groupings that have potential for clinical trial development. With the ultimate aim...

Cite
Le Du F, Eckhardt BL, Lim B, et al. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget. 2015;6(15):12890-908doi: 10.18632/oncotarget.3849.
Le Du, F., Eckhardt, B. L., Lim, B., Litton, J. K., Moulder, S., Meric-Bernstam, F., Gonzalez-Angulo, A. M., & Ueno, N. T. (2015). Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget, 6(15), 12890-908. https://doi.org/10.18632/oncotarget.3849
Le Du, Fanny, et al. "Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?." Oncotarget vol. 6,15 (2015): 12890-908. doi: https://doi.org/10.18632/oncotarget.3849
Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget. 2015 May 30;6(15):12890-908. doi: 10.18632/oncotarget.3849. PMID: 25973541; PMCID: PMC4536987.
Copy Download .nbib Format: NLM
Novel therapies for triple-negative breast cancer.

Clinical advances in hematology & oncology : H&O

Nanda R.
PMID: 33406056
Clin Adv Hematol Oncol. 2020 Dec;18(12):799-801.

No abstract available.

Cite
Nanda R. Novel therapies for triple-negative breast cancer. Clin Adv Hematol Oncol. 2020;18(12):799-801
Nanda, R. (2020). Novel therapies for triple-negative breast cancer. Clinical advances in hematology & oncology : H&O, 18(12), 799-801.
Nanda, Rita. "Novel therapies for triple-negative breast cancer." Clinical advances in hematology & oncology : H&O vol. 18,12 (2020): 799-801.
Nanda R. Novel therapies for triple-negative breast cancer. Clin Adv Hematol Oncol. 2020 Dec;18(12):799-801. PMID: 33406056.
Copy Download .nbib Format: NLM
Subtyping of triple-negative breast cancer.

Clinical advances in hematology & oncology : H&O

Mayer IA.
PMID: 24896546
Clin Adv Hematol Oncol. 2013 Nov;11(11):731-2.

No abstract available.

Cite
Mayer IA. Subtyping of triple-negative breast cancer. Clin Adv Hematol Oncol. 2013;11(11):731-2
Mayer, I. A. (2013). Subtyping of triple-negative breast cancer. Clinical advances in hematology & oncology : H&O, 11(11), 731-2.
Mayer, Ingrid A. "Subtyping of triple-negative breast cancer." Clinical advances in hematology & oncology : H&O vol. 11,11 (2013): 731-2.
Mayer IA. Subtyping of triple-negative breast cancer. Clin Adv Hematol Oncol. 2013 Nov;11(11):731-2. PMID: 24896546.
Copy Download .nbib Format: NLM
Comprehensive identification and characterization of somatic copy number alterations in triple‑negative breast cancer.

International journal of oncology

Li Z, Zhang X, Hou C, Zhou Y, Chen J, Cai H, Ye Y, Liu J, Huang N.
PMID: 31894314
Int J Oncol. 2020 Feb;56(2):522-530. doi: 10.3892/ijo.2019.4950. Epub 2019 Dec 23.

Triple‑negative breast cancer (TNBC) accounts for ~15% of all breast cancer diagnoses each year. Patients with TNBC tend to have a higher risk for early relapse and a worse prognosis. TNBC is characterized by extensive somatic copy number alterations...

Cite
Li Z, Zhang X, Hou C, et al. Comprehensive identification and characterization of somatic copy number alterations in triple‑negative breast cancer. Int J Oncol. 2019;56(2):522-530doi: 10.3892/ijo.2019.4950.
Li, Z., Zhang, X., Hou, C., Zhou, Y., Chen, J., Cai, H., Ye, Y., Liu, J., & Huang, N. (2020). Comprehensive identification and characterization of somatic copy number alterations in triple‑negative breast cancer. International journal of oncology, 56(2), 522-530. https://doi.org/10.3892/ijo.2019.4950
Li, Zaibing, et al. "Comprehensive identification and characterization of somatic copy number alterations in triple‑negative breast cancer." International journal of oncology vol. 56,2 (2020): 522-530. doi: https://doi.org/10.3892/ijo.2019.4950
Li Z, Zhang X, Hou C, Zhou Y, Chen J, Cai H, Ye Y, Liu J, Huang N. Comprehensive identification and characterization of somatic copy number alterations in triple‑negative breast cancer. Int J Oncol. 2020 Feb;56(2):522-530. doi: 10.3892/ijo.2019.4950. Epub 2019 Dec 23. PMID: 31894314; PMCID: PMC6959384.
Copy Download .nbib Format: NLM
Microarray-based SNP genotyping to identify genetic risk factors of triple-negative breast cancer (TNBC) in South Indian population.

Molecular and cellular biochemistry

Aravind Kumar M, Singh V, Naushad SM, Shanker U, Lakshmi Narasu M.
PMID: 28918577
Mol Cell Biochem. 2018 May;442(1):1-10. doi: 10.1007/s11010-017-3187-6. Epub 2017 Sep 16.

In the view of aggressive nature of Triple-Negative Breast cancer (TNBC) due to the lack of receptors (ER, PR, HER2) and high incidence of drug resistance associated with it, a case-control association study was conducted to identify the contributing...

Cite
Aravind Kumar M, Singh V, Naushad SM, et al. Microarray-based SNP genotyping to identify genetic risk factors of triple-negative breast cancer (TNBC) in South Indian population. Mol Cell Biochem. 2017;442(1):1-10doi: 10.1007/s11010-017-3187-6.
Aravind Kumar, M., Singh, V., Naushad, S. M., Shanker, U., & Lakshmi Narasu, M. (2018). Microarray-based SNP genotyping to identify genetic risk factors of triple-negative breast cancer (TNBC) in South Indian population. Molecular and cellular biochemistry, 442(1), 1-10. https://doi.org/10.1007/s11010-017-3187-6
Aravind Kumar, M, et al. "Microarray-based SNP genotyping to identify genetic risk factors of triple-negative breast cancer (TNBC) in South Indian population." Molecular and cellular biochemistry vol. 442,1 (2018): 1-10. doi: https://doi.org/10.1007/s11010-017-3187-6
Aravind Kumar M, Singh V, Naushad SM, Shanker U, Lakshmi Narasu M. Microarray-based SNP genotyping to identify genetic risk factors of triple-negative breast cancer (TNBC) in South Indian population. Mol Cell Biochem. 2018 May;442(1):1-10. doi: 10.1007/s11010-017-3187-6. Epub 2017 Sep 16. PMID: 28918577.
Copy Download .nbib Format: NLM
Ensemble outlier detection and gene selection in triple-negative breast cancer data.

BMC bioinformatics

Lopes MB, Veríssimo A, Carrasquinha E, Casimiro S, Beerenwinkel N, Vinga S.
PMID: 29728051
BMC Bioinformatics. 2018 May 04;19(1):168. doi: 10.1186/s12859-018-2149-7.

BACKGROUND: Learning accurate models from 'omics data is bringing many challenges due to their inherent high-dimensionality, e.g. the number of gene expression variables, and comparatively lower sample sizes, which leads to ill-posed inverse problems. Furthermore, the presence of outliers,...

Cite
Lopes MB, Veríssimo A, Carrasquinha E, et al. Ensemble outlier detection and gene selection in triple-negative breast cancer data. BMC Bioinformatics. 2018;19(1):168doi: 10.1186/s12859-018-2149-7.
Lopes, M. B., Veríssimo, A., Carrasquinha, E., Casimiro, S., Beerenwinkel, N., & Vinga, S. (2018). Ensemble outlier detection and gene selection in triple-negative breast cancer data. BMC bioinformatics, 19(1), 168. https://doi.org/10.1186/s12859-018-2149-7
Lopes, Marta B, et al. "Ensemble outlier detection and gene selection in triple-negative breast cancer data." BMC bioinformatics vol. 19,1 (2018): 168. doi: https://doi.org/10.1186/s12859-018-2149-7
Lopes MB, Veríssimo A, Carrasquinha E, Casimiro S, Beerenwinkel N, Vinga S. Ensemble outlier detection and gene selection in triple-negative breast cancer data. BMC Bioinformatics. 2018 May 04;19(1):168. doi: 10.1186/s12859-018-2149-7. PMID: 29728051; PMCID: PMC5936001.
Copy Download .nbib Format: NLM
Translating the molecular message of triple-negative breast cancer into targeted therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research

Vidula N, Rugo HS.
PMID: 25351747
Clin Cancer Res. 2015 Apr 01;21(7):1511-3. doi: 10.1158/1078-0432.CCR-14-2532. Epub 2014 Oct 28.

Triple-negative breast cancer (TNBC) has a poor prognosis with limited treatment options. Genomic analysis of TNBCs offers the opportunity to decode TNBC into biologically relevant subtypes with unique molecular targets. With further research, these findings may be translated into...

Cite
Vidula N, Rugo HS. Translating the molecular message of triple-negative breast cancer into targeted therapy. Clin Cancer Res. 2014;21(7):1511-3doi: 10.1158/1078-0432.CCR-14-2532.
Vidula, N., & Rugo, H. S. (2015). Translating the molecular message of triple-negative breast cancer into targeted therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 21(7), 1511-3. https://doi.org/10.1158/1078-0432.CCR-14-2532
Vidula, Neelima, and Rugo, Hope S. "Translating the molecular message of triple-negative breast cancer into targeted therapy." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 21,7 (2015): 1511-3. doi: https://doi.org/10.1158/1078-0432.CCR-14-2532
Vidula N, Rugo HS. Translating the molecular message of triple-negative breast cancer into targeted therapy. Clin Cancer Res. 2015 Apr 01;21(7):1511-3. doi: 10.1158/1078-0432.CCR-14-2532. Epub 2014 Oct 28. PMID: 25351747.
Copy Download .nbib Format: NLM
MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer.

Artificial cells, nanomedicine, and biotechnology

Tang Q, Ouyang H, He D, Yu C, Tang G.
PMID: 31284781
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2800-2809. doi: 10.1080/21691401.2019.1638791.

Triple-negative breast cancer (TNBC) is a distinct subtype of breast cancer characterized by high recurrence rates and poor prognosis compared to other breast cancers. MicroRNAs (miRNAs) are small non-coding RNAs that regulate the expression of various post-transcriptional gene and...

Cite
Tang Q, Ouyang H, He D, et al. MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer. Artif Cells Nanomed Biotechnol. 2019;47(1):2800-2809doi: 10.1080/21691401.2019.1638791.
Tang, Q., Ouyang, H., He, D., Yu, C., & Tang, G. (2019). MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer. Artificial cells, nanomedicine, and biotechnology, 47(1), 2800-2809. https://doi.org/10.1080/21691401.2019.1638791
Tang, Qian, et al. "MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer." Artificial cells, nanomedicine, and biotechnology vol. 47,1 (2019): 2800-2809. doi: https://doi.org/10.1080/21691401.2019.1638791
Tang Q, Ouyang H, He D, Yu C, Tang G. MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2800-2809. doi: 10.1080/21691401.2019.1638791. PMID: 31284781.
Copy Download .nbib Format: NLM
Progress in systemic therapy for triple-negative breast cancer.

Frontiers of medicine

Mo H, Xu B.
PMID: 32789731
Front Med. 2021 Feb;15(1):1-10. doi: 10.1007/s11684-020-0741-5. Epub 2020 Aug 13.

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a heterogeneous genetic profile. Chemotherapy exhibits substantial activity in a small subset of these patients. Drug resistance is inevitable. Major progress has been made in the...

Cite
Mo H, Xu B. Progress in systemic therapy for triple-negative breast cancer. Front Med. 2020;15(1):1-10doi: 10.1007/s11684-020-0741-5.
Mo, H., & Xu, B. (2021). Progress in systemic therapy for triple-negative breast cancer. Frontiers of medicine, 15(1), 1-10. https://doi.org/10.1007/s11684-020-0741-5
Mo, Hongnan, and Xu, Binghe. "Progress in systemic therapy for triple-negative breast cancer." Frontiers of medicine vol. 15,1 (2021): 1-10. doi: https://doi.org/10.1007/s11684-020-0741-5
Mo H, Xu B. Progress in systemic therapy for triple-negative breast cancer. Front Med. 2021 Feb;15(1):1-10. doi: 10.1007/s11684-020-0741-5. Epub 2020 Aug 13. PMID: 32789731.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries